Neumora Launches With $500m To Advance Personalized Neuroscience Drugs
Funding Includes $100m Under New Amgen Deal
Combining biological insights with data science, the start-up emerges from stealth mode after two years of assembling its technology platform and R&D pipeline based on internal and external know-how.
You may also be interested in...
The company will focus on core therapeutics areas like oncology and cardiovascular disease, but left open the possibility of future work in neuroscience with a genetic basis for drug development.
BlackThorn's series B round will fund the use of AI and machine learning via its PathFinder platform and academic collaborations for the development of targeted therapies.
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.